Introduction
Idiopathic pulmonary fibrosis (IPF) is a devastating chronic fibrotic lung disease with a median survival of 2-3 year [1] . Options for the treatment of IPF are limited. Only two drugs, Pirfenidone and nintedanib, have demonstrated efficacy in slowing fibrosis progression in patients with mild to moderate IPF [2, 3] . Therefore, novel treatment options are sorely needed. The current paradigm on the underlying pathogenic mechanisms postulates that IPF is an "epithelial-fibroblastic disease", i.e. a fibroproliferative disorder preceded by alveolar epithelial injury and activation, with fibrotic foci representing the primary sites of injury and aberrant repair [1] . The precise signals triggering the aberrant and sustained wound healing response in IPF remain elusive, and represent an area of intense investigation. Evidence for diffuse infiltration of immune cells in the fibrotic lung also strongly suggest that autoimmunity plays a role in the course of the disease. Accordingly, immunomodulatory therapies are currently being evaluated in early-phase clinical trials [4, 5] .
Matriptase belongs to the recently identified Type II-transmembrane serine protease family [6] . Membrane anchorage enables matriptase to initiate pericellular proteolysis in the microenvironment, and to interact with vicinal membrane proteins on the same cell surface and/or on neighbouring cells. Matriptase activity is regulated by hepatocyte growth factor activator inhibitor type (HAI)-1, through formation of a stoichiometric 1:1 complex. Over the last decade, compelling evidence has demonstrated that matriptase deregulation is influential in a broad variety of pathological processes, including cancer and skin diseases [6, 7] . Three major macromolecular substrates of matriptase have been identified: hepatocyte growth factor, Protease-activated receptor-2 and urokinase-type plasminogen activator [6] . Through the cleavage of these substrates, matriptase triggers specific responses including cell proliferation, migration, inflammatory cytokine production, inflammatory cell recruitment, hyperplasia and fibrosis [8, 9] . These responses are crucial in fibrotic diseases [10, 11] , but the role of matriptase in fibrotic disorders has thus far never been explored.
We recently established a link between Protease-activated receptor(PAR)-2 and pulmonary fibrosis progression in humans and mice [12] . PAR-2 belongs to the G-proteincoupled receptor superfamily. Its activation by proteolytic cleavage triggers multiple cell signaling pathways, the functional consequences of which are crucial in pathologies such as aberrant wound repair mechanisms [13] . However, the relevant PAR-2 agonists involved in 6 IPF remain unknown. Considering that matriptase is expressed physiologically in murine and human lung [14] , orchestrates tissue remodelling through its potent trypsin-like activity and is able to activate PAR-2, in the present study, we explore whether matriptase is implicated in the progression of human and experimental pulmonary fibrosis.
Materials and Methods
Methodology for the murine bleomycin model, collagen quantification, qRT-PCR, cell culture studies, histology and immunohistochemistry can be found in the online supplement.
Human Tissues
Lung tissue was obtained from 61 patients with IPF (8 females, 53 males; mean age 57.6±7.5 years), and 43 control subjects (patients undergoing lung surgery for removal of a primary lung tumor; mean age 62.5±13.8, 17 females, 26 males). Control tissues were obtained from noninvolved segment, remote from the solitary tumor lesion, and normalcy of control lungs was verified histologically as described previously [15, 16] . Primary fibroblasts were isolated as described in [15] . The study protocol was approved by the institutional Ethics committee 
Animals
C57BL/6N mice were from Janvier Labs (Le Genest Saint Isle, France). When indicated, 0.5 mg camostat mesilate (CM) treatment was initiated 7 days after bleomycin challenge. CM was administrated intranasally every other day from day 7-14. Matriptase hypomorphic mice have been described previously [17] . Briefly, these mice possess one null allele and one allele in which a reporter gene trap is inserted into the matriptase locus and disrupts gene expression. A low level of alternative splicing in the gene trap allele results in low level synthesis of full length matriptase, which is sufficient to enable mouse survival. Experiments with matriptase hypomorphic mice were littermate controlled from mice generated from heterozygous crosses [18] . The bleomycin murine model of pulmonary fibrosis was set up as described previously [19] . Additional details are provided in the online supplement.
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Statistical Analyses
Statistical analyses were conducted using GraphPad Prism (GraphPad Software, San Diego, CA). Data are expressed as mean ± SEM. Comparisons between two groups were analyzed using two-tailed unpaired t-tests when the data where normally distributed, otherwise MannWhitney analysis was performed. P values of <0.05 were considered to indicate a statistically significant difference.
Results
Increased matriptase expression and activity in the lungs of IPF patients
We first investigated whether the expression and activity of matriptase are deregulated in IPF. The mRNA levels of matriptase were determined in human lung tissue specimen from controls and IPF patients using qRT-PCR. As shown in Table I and Figure 1A , in IPF tissues, matriptase mRNA was significantly upregulated (by 1.6±0.1-fold) compared to control. We confirmed matriptase upregulation by immunoblotting. As shown in Figure 1B , in control lungs (lanes 1-6), matriptase expression is low, and increased by 2.25 fold in IPF lungs (lanes [8] [9] [10] [11] [12] . Additionally, consistent with previous studies [20, 21] , PAR-2 expression was upregulated in IPF lung (3.5±2-fold) ( Figure 1B ). Subsequently, we determined the proteolytic activity of matriptase in control and IPF tissues by monitoring the cleavage of its highly specific fluorogenic peptide substrate t-butyloxycarbonyl Boc-Gln-Ala-Arg-MCA (Boc-QAR-AMC) [7, 22] . Figure 1C shows that the proteolytic activity significantly increased (206±65%) in IPF lungs compared to controls. Consistently, increased matriptase antigen level and activity were detected in BALF IPF patients (Supplemental Figure E1 ).
Deregulation of matriptase activity often relates to an imbalance with its endogenous inhibitor HAI-1. Hence, we determined the HAI-1 mRNA levels by qPCR and determined the ratio of matriptase/HAI-1 mRNA expression in control versus IPF lungs, as previously described [23] . In IPF tissues, we observed a 1.2-fold increase in HAI-1 mRNA, and the ratio matriptase/HAI-1 was slightly upregulated in IPF patients (Table 1) .
Next, we examined the cellular distribution of matriptase in lung biopsies of IPF patients. Immunohistochemical staining showed prominent matriptase immunoreactivity, in macrophages and epithelial cells overlying fibroblast foci, and a weaker staining in (myo)fibroblasts of these foci ( Figure 1D-I) . Endothelium staining was even weaker (not 8 shown). In contrast, only sparse staining of alveolar type II cells (AECs) and monocytes was observed in the nonfibrotic part of the lung of these patients ( Figure 1J ). There was no detectable signal for similar sections stained with an isotype-specific control antibody ( Figure   1K ). Finally, using primary IPF AEC and fibroblasts derived from a different (German) cohort, we assessed the relative expression of matriptase by qPCR and confirmed that matriptase mRNA level is higher in fibrotic AECs, and weaker in fibrotic fibroblasts ( Figure   1L ).
Modulation of matriptase expression in vitro in pulmonary cells
We next analysed the modulation of matriptase expression in pulmonary cells.
Western blots of primary human pulmonary fibroblasts derived from IPF tissues (figure 2A) showed 1.7±0.4-fold higher matriptase expression (lanes 6-9) than from control fibroblasts (lanes 1-5). Since TGF-β is a master switch in the development of fibrosis during IPF [24], we also assessed its action on pulmonary cells. Stimulation of control (lanes [10] [11] [12] [13] [14] or fibrotic (lanes 15-18) fibroblasts for 48h by TGF-β (1ng/mL) robustly enhanced matriptase expression by 3.1±0.5 and 5.1±1.5-fold respectively (Figure 2A) . Consistent with previous studies [20, 21], PAR-2 was upregulated in IPF and TGF-β-stimulated control fibroblasts (by 2.4±0.8-and 4.5±0.8-fold respectively). To our knowledge, the action of TGF-β on PAR-2 expression in IPF fibroblasts has never been assessed. We observed in TGF-β-stimulated IPF fibroblasts that PAR-2 expression was unchanged (p=0.057) (Figure 2A ). The effects of TGF-β on matriptase expression were also examined in epithelial pulmonary cells and in Normal Human Lung Fibroblasts (NHLF). TGF-β induced matriptase upregulation by 4.5±1-fold in NHLF ( Figure 2B ) and by 1.6±0.3-fold in epithelial pulmonary cells ( Figure 2D, lanes 1-3) . We also assessed the effects of matriptase on its own expression. We observed that, while 48h stimulation with 0-10nM recombinant matriptase (which displays a potent activity similar to endogenous matriptase [7] ) had no effect on fibroblasts ( Figure 2C ), matriptase efficiently upregulated its own expression in epithelial pulmonary cells at 1 and 10nM (by 1.9±0.3-and 2.3±0.2-fold respectively) ( Figure 2D , lanes 4-5)
Matriptase evokes fibroproliferative responses in vitro via PAR-2 activation
We next characterized the signalling elicited by matriptase in pulmonary cells. Control fibroblasts were stimulated for 30 minutes with 0-10 nM matriptase, or for 0-60 minutes with 1nM matriptase. We analyzed the phosphorylation of ERK1/2 and Akt, which mediate 9 influential signaling pathways in pulmonary fibrogenesis [25] . Figure 3A shows that matriptase stimulated a time-and dose-dependent phosphorylation of both kinases.
Furthermore, to determine whether PAR-2 mediates matriptase-induced signalling, cells were preincubated for 30 minutes with the PAR-2 blocking antibody, SAM-11 [26, 27] , and subsequently stimulated for 10 min with 1nM matriptase. Pretreatment with SAM-11 strongly reduced the matriptase-induced phosphorylation of ERK1/2 or Akt ( Figure 3A) . Similar results were obtained with epithelial pulmonary cells ( Figure 3B ) and NHLF (not shown).
Altogether, these data demonstrate that matriptase signals to pulmonary cells via PAR-2 activation.
The effects of 48h incubation with 0-10nM matriptase on cell proliferation were also assessed by a WST-1 assay. As shown in figure 3C , 1nM and 10nM matriptase significantly Figure 3D ). We also analyzed the effects of matriptase on fibroblast migration in a modified Boyden chamber.
As shown on Figure 3E , 1nM matriptase enhanced cell migration by 175±46 %. This effect was reversed by 10 µM GB-88, underlying PAR-2 involvement in matriptase-mediated cell migration. We subsequently examined whether matriptase triggers fibroblast activation, and stimulate ECM component synthesis. As shown in Figure 3F Figure E3) , or the PAR-2 antagonist GB88 (10 µM), reversed matriptaseinduced protein expression ( Figure 3G ).
Overall, these data implicate a contributing role for matriptase in IPF pathogenesis, prompting us to further analyse the effects of modulating matriptase in experimental bleomycin-induced pulmonary fibrosis.
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Matriptase expression and activity are increased during experimental pulmonary fibrosis Mice subjected to a single orotracheal instillation of bleomycin developed pulmonary fibrosis over a 2-week time course (inflammatory phase: day 1-7, fibrosing phase day [7] [8] [9] [10] [11] [12] [13] [14] . Figure 4A shows data for the temporal modulation of matriptase expression and activity in murine lungs in this experimental model. Matriptase activity significantly increased by day 7 (by 388±114%) and day 14 (by 587±50%) ( Figure 4A, top panel) . Accordingly, immunoblotting confirmed an increase in pulmonary matriptase expression 14 days after bleomycin instillation ( Figure 4A, bottom panel) . Hence, we assessed the efficacy of the matriptase inhibitor camostat mesilate (CM), when administrated from day 7 onwards after the bleomycin challenge (delayed treatment), on pulmonary fibrosis development.
Inhibition of matriptase by camostat mesilate attenuates pulmonary fibrogenesis in vivo
CM is clinically used to treat pancreatitis. We initiated a delayed treatment by CM at the same dose range administered to patients [32] . CM treatment significantly reduced matriptase activity in murine lung homogenates 14 days after bleomycin challenge (853±130% to 381±63 %) ( Figure 4B ). Additionally, the loss in body weight (determined from day 7 onwards) in the bleomycin group was significantly attenuated in the CM-treated group ( Figure 4C ). We next quantified total pulmonary collagen content 14 days after bleomycin challenge. The collagen content strongly increased after bleomycin treatment (from 1261±463 to 2408±747 µg/g lung), and was blunted in the bleomycin+CM group (1527±664 µg/g lung) ( Figure 4D ). Accordingly, histologic assessment of the lung structure revealed that delayed CM treatment significantly attenuated the alveolar wall thickening due to inflammation and fibrosis ( Figure 4E , bottom panels). The Ashcroft scoring system confirmed that CM treatment significantly reduced the severity of the lesions induced by bleomycin exposure (2.7±0.3 versus 4.9±0.2, respectively) ( Figure 4F ). Accordingly, a reduced fibrosis score determined on semi-quantitative assessment of Masson's trichrome staining was observed in CM-treated animals ( Figure 4G ). A potential mechanism by which matriptase inhibition is protective could be by preventing myofibroblast differentiation.
Indeed, semi-quantitative assessment of α-SMA staining revealed a markedly reduced α-SMA expression in bleomycin+CM versus bleomycin groups (1.3±0.7 versus 3.61±0.1, Figure 4H ).
We next assessed TGF-β expression and signaling. As shown in Figure 4I , TGF-β mRNA was strongly upregulated upon bleomycin challenge (by 177±50%), while in the bleomycin+CM-treated group, it was significantly reduced. Accordingly, Smad-2 phosphorylation was significantly increased by bleomycin, and was markedly attenuated by CM (respectively 2.1±0.7-versus 1.2±.4-fold increase).
Finally, we determined the effects of CM on the inflammatory response. The total number of macrophages in BALF was increased by bleomycin, but remained unchanged in the CM-treated group ( Figure 4J ). The levels of the cytokines TNF-α, IL-6, and MCP-1 were also unaffected by CM treatment (data not shown). Thus, CM does not seem to modulate the inflammatory responses. Altogether, these data suggest that CM treatment affords protection from bleomycin-induced pulmonary fibrosis, with the prevailing mechanisms seeming to be antifibrotic rather than anti-inflammatory.
Consequences of matriptase genetic down-regulation in experimental pulmonary fibrogenesis
Finally, we assessed the effects of genetic matriptase depletion in pulmonary fibrosis.
Matriptase deficiency is lethal [33] . Hence, we used matriptase hypomorphic mice, which express low levels of pulmonary matriptase [17] . Indeed, we observed that Matriptase hypomorphic mice expressed 7.1±6% of the matriptase mRNA levels detected in lung tissues of littermate control mice ( Figure 5A ). Matriptase hypomorphic mice and controls were subjected to bleomycin-induced pulmonary fibrosis and sacrificed 14 days after bleomycin challenge. Quantification of total pulmonary collagen content in controls revealed that collagen was significantly increased after bleomycin treatment (from 1232±342 to 2049±569 µg/g lung). Interestingly, in the hypomorphic mice, there was no significant difference in collagen content between the saline-or bleomycin-treated groups (1369±286 versus to 1070±462 µg/g lung) ( Figure 5B). Histologic assessment of the lung structure revealed that in matriptase hypomorphic mice, bleomycin-induced lung injury was reduced compared to the controls ( Figure 5C ). Indeed, the severity of the lesions was reduced on the Ashcroft scale (2.7±1 versus 5±1 respectively, Figure 5D ). Quantitative assessment of α-SMA staining demonstrated that, after bleomycin treatment, α-SMA expression was significantly reduced in matriptase hypomorphic mice compared to controls ( Figure 5E ). Finally, analysis of TGF-β expression and signaling in the two groups of mice revealed that, again, bleomycin elicited a significant increase of TGF-β mRNA in the control mice. In matriptase hypomorphic mice, there was no significant difference between saline and bleomycin groups. Accordingly, Smad-12 2 phosphorylation was increased by bleomycin in control, but not in hypomorphic mice (respectively by 2.5±0.8 versus 1.4±0.5-fold; Figure 5F ) Hence, genetic matriptase down-regulation inhibits the bleomycin-induced collagen secretion, lung injury and α-SMA expression with an efficiency comparable to that of pharmacological inhibition with camostat mesilate.
Discussion
The present study establishes for the first time a link between the membrane-anchored serine protease matriptase and IPF. Increased matriptase expression and activity were detected in human IPF specimen compared to controls. In vitro, we observed in pulmonary cells a remarkable plasticity in matriptase expression in response to TGF-β. Of note, the fibroblastic modulation of PAR-2 is akin of that observed for matriptase. PAR-2 is a major matriptase substrate [6] , and is involved in IPF [12, 21, 34, 35] . Indeed, we observed that matriptase triggers key features involved in IPF via PAR-2 activation. Strikingly, matriptase orchestrates fibroblast activation (characterized by proliferation, migration, differentiation and protein synthesis) while it contributes to pulmonary epithelial cell loss. Because membraneanchorage enables matriptase to interact with vicinal proteins on the same cell surface or on neighbor cells, it may be hypothesized that epithelial and/or fibroblastic matriptase contribute to the aberrant epithelial-mesenchymal crosstalk characterizing IPF, eventually leading to sustained pathological wound healing response. Accordingly, in our experimental model of bleomycin-induced pulmonary fibrosis, matriptase genetic down-regulation effectively limits fibrosis development, collagen deposition, myofibroblast activation, TGF-β expression and signaling, thereby establishing a causal role for matriptase in pulmonary fibrosis pathogenesis.
We showed that, similar to the results obtained with matriptase hypomorphic mice, delayed CM treatment (i.e. initiated after the inflammatory phase of the model, 7 days after the bleomycin challenge) substantially reduces pulmonary fibrosis. CM has successfully been used in experimental models of liver, pancreatic and renal fibrosis [36] [37] [38] , and the antifibrogenic effect of CM were attributable (at least partly) to reduced TGF-β expression and signaling. So far, CM efficiency had never been assessed in pulmonary fibrosis, and our results are consistent with these findings. CM has a relatively narrow inhibition spectrum 13 among serine proteases. Indeed, besides matriptase, it displays a very high specificity for trypsin, and, to a lower extent, prostasin [29, 31] , the expressions of which were unchanged in IPF lungs (data not shown). Because CM is already used in clinics, its safety and tolerance are well established [31, 32] . All these advantages would be particularly favorable for long-term treatment in IPF patients.
Several issues are relevant to interpreting these data. First, one might hypothesize that the CM effects may be mediated through thrombin inhibition. However, we demonstrated comparable antifibrotic effects of genetic and pharmacological matriptase depletion.
Furthermore, in vitro, thrombin activity is unaffected by a dose of CM which completely inhibits matriptase activity (Supplementary Figure E3) . Nevertheless, a possible involvement of other unknown serine protease(s) that is/are inhibited by CM in the pathogenesis of IPF cannot be excluded. Second, the antifibrotic effects of CM might be due to direct bleomycin inhibition. However, CM treatment in the present study was delayed, and so is unlikely to interfere with the course of events triggered by bleomycin immediately after its delivery. In the present study, matriptase was upregulated by ~1.56-fold in IPF. Interestingly, another study demonstrated that, in mice, a modest overexpression (1.2-to 1.4-fold) of matriptase in the skin was sufficient to cause spontaneous squamous cell carcinoma in the absence of other environmental or genetic challenges, and dramatically potentiated carcinogen-induced tumor formation. Regulation of matriptase activity by HAI-1 overexpression negated the oncogenic effects of matriptase [44] . These observations are consistent with the results of our study. We find that a modest increase in matriptase expression and activity is associated with pulmonary fibrogenesis, and matriptase depletion, either using camostat mesilate, or genetic down-regulation, ablates this phenotype.
Additionally, the reported matriptase-induced malignant conversion was preceded by progressive dermal hyperplasia and fibrosis, observations that are striking in the context of IPF. Indeed, the incidence of lung cancer in patients with IPF is higher than the general population [45] . Thus, it is tempting to speculate that a modest overexpression of matriptase in human lung contributes to higher tumor susceptibility, but the identification of the specific 14 molecular events that enable matriptase-induced transformation in the lung remains a substantial challenge.
To our knowledge, this is the first report for matriptase expression and modulation during pathogenesis in human pulmonary fibroblasts. Noteworthy, in the fibroblastic foci of IPF lungs, fibroblast staining for matriptase was weaker than in overlying epithelium.
Moreover, in line with heterogeneity of the fibroblast population [46] , not all fibroblasts were positive for matriptase. Nevertheless, our in vitro data confirmed that matriptase expression is increased in primary IPF fibroblasts compared to controls, and strongly driven by TGF-β in Assessment of the severity of pulmonary fibrosis on Ashcroft scale 14 days after saline (white bars), or bleomycin (black bars) instillation. Depicted is the mean ± SEM histological score, n 
Supplemental methods
Human Tissues
Lung tissue was obtained from 61 patients with IPF (8 females, 53 males; mean age 57.6 ± 7.5 years), and 43 control subjects (patients undergoing lung surgery for removal of a primary lung tumor; mean age 62.5 ± 13.8, 17 females, 26 males). Control tissues were derived from normal lung sample, obtained from a noninvolved segment, remote from the solitary tumor lesion. as described previously. Normalcy of control lungs was verified histologically (1, 2).
Primary fibroblasts were isolated as described in ( 
Isolation of primary IPF human alveolar epithelial cells (phATII) and IPF fibroblasts (German cohort)
Isolation of primary human alveolar epithelial cells was conducted as previously described (4) with some modifications. In brief, tissue specimens were manually minced and digested with a dispase/collagenase mixture (Roche) for 2h at 37°C. Samples were subsequently filtered through nylon meshes and the single cell suspension was centrifuged at 400 g, 4°C for 10 minutes. The cell pellet was resuspended in DMEM/F12 Medium and then layered onto a discontinuous Percoll density gradient (1.04-1.09 g/ml) and centrifuged at 300 g for 20 minutes. Cells in the interphase representing macrophages and alveolar epithelial cells were recovered and depleted for Macrophages using CD45 specific magnetic beads (Miltenyi Biotec) according to the manufacturer's instructions. Collected cell suspension was centrifuged and the cell pellet was snapped frozen in liquid nitrogen.
Isolation and culture of primary human lung fibroblasts (phFB)
Isolation of primary human lung fibroblasts was performed as previously described in (5). In brief, human lung tissue was digested using 1mg/ml Collagenase I (Biochrom, Cambridge, UK) for 2 hours at 37 °C. Samples were filtered through nylon meshes to obtain a single cell suspension, which was subsequently centrifuged at 400 g, 4°C for 5 minutes. Cell pellets were resuspended in DMEM/F-12 medium (Life Technologies, Carlsbad, CA, USA) supplemented with 20% fetal bovine serum (Pan Biotech, Aidenbach, Germany) and 3 Penicillin/Streptomycin (Life Technologies). Cells were cultured on 10 cm cell-culture dishes with a media change at every other day.
Antibodies and Reagents
The following antibodies were used in this study: PAR-2 (SAM11) 
RNA isolation and quantitative reverse transcription polymerase chain reaction.
Total RNA was extracted using NucleoSpin1 RNA II extraction kit (Macherey Nagel, Hoerd, France) according to the manufacturer's protocol, and cDNAs were generated by reverse transcription using SuperScript II (Invitrogen). To quantify mRNA expression of the indicated genes, quantitative PCR was performed using fluorogenic SYBR Green with specific primers from GenScript and the Sequence Detection System 7700 (Applied Biosystems). Transcripts of Ubiquitin (UBC) for human and Beta2-Microglobulin (B2M) for mouse were used as reference genes in all qRT-PCR reactions. Results were expressed in fold changes compared to control, subsequently to normalization to the reference gene Western Blot 6 of the filter were enumerated using an ocular micrometer and the total number of cells migrated was counted. Data are presented as relative migration compared to control, and represent mean±SEM of 4 different experiments.
Animals
C57BL/6N mice were purchased from Janvier Labs (Le Genest Saint Isle, France). When indicated, 0.5 mg camostat mesilate (CM) treatment was initiated 7 days after bleomycin challenge, and administrated intranasally every other day from day 7 until day 14. St14 hypomorphic mice were generated by Pr Thomas Bugge and have been described previosuly (8) (9) (10) . Briefly, these mice possess one null allele and one allele in which a reporter gene trap is inserted into the matriptase locus and disrupts gene expression. A low level of alternative splicing in the gene trap allele results in low level synthesis of full length matriptase, which is sufficient to enable mouse survival (9) . All experiments performed with St14 hypomorphic mice were littermate controlled from mice generated from heterozygous crosses (8) . For all experiments, adult mice (8-10 week-old) received intratracheally bleomycin hydrochloride as previously described (11) . Mice referred to as controls received the same volume of sterile phosphate-buffered saline. Mice were sacrificed at the indicated time points after bleomycin challenge. Lung tissues excision for histological analyses, bronchoalveolar lavage (BAL) and BAL cell count was performed as previously described (11) . All experiments were performed in compliance with the Institutional Standards for Use of Laboratory Animals.
Histopathological Assessment of Pulmonary Fibrosis
Following fixation, entire mouse lungs were embedded in paraffin. Four-micron thick sections were stained with H&E, α-actin and Masson's trichrome, according to routine procedures. Different systems were used to assess fibrosis. To prevent observer bias, all histological specimens were randomly numbered and interpreted in a blinded fashion. For each scoring, between 5 and 10 fields in lung lobes (depending on the size and the homogeneity of the histological changes) were examined using light microscopy (×200 magnification). Fields were examined to cover each entire lobe and were discarded if nonrepresentative areas or if they included large airways and vessels as described in (12) . The mean score for each lobe 7 was expressed as the average of scores determined in each field. The severity of the lesions was determined by using the Ashcroft scoring system (13) . Briefly, each field examined was assessed individually for the severity of fibrotic changes and allotted a score from 0 (normal) to 8 (total fibrosis) using a predetermined scale of severity (numerical fibrotic scale). After examination of the whole section, the mean of the scores from all fields was taken as the fibrotic score. Semi quantitative assessment of α-actin and Masson's trichrome was perfomed by grading the stained slides in a blinded fashion as follows: α-actin was graded on a 0 to 4 scale as follows : 0 = absent staining, 1 = weak staining with focal distribution, 2 = moderate with focal distribution, 3 = strong with focal distribution or weak and diffuse, and 4 = strong and diffuse (14) . Masson's trichrome staining was graded on a 0 to 3 as in (15) : grade 0, normal lung; grade 1, minimal lesion (lesion area <20%); grade 2, moderate lesion (lesion area, 20-50%); or grade 3, severe lesion (lesion area >50%).
Quantification of secreted collagen
For quantification of total secreted collagen, the Sircol assay was performed according to manufacturer's instructions (Biocolor, Carrickfergus, UK). The Sircol assay was used without incorporating the recent modified method with a pepsin digestion step described by Lareu and colleagues (16) . More specifically, according to the manufaturer's recommendation for soft tissue handling, to minimize background due to the interference of serum proteinsespecially albumin in cell culture medium-with the Sircol reagent, the lungs were flushed before excision, then lung samples were further diced and washed in PBS to clear blood 
